ORA 14th Annual Meeting
The ORA 2015 Annual Meeting is being held May 22-24, 2015.
New Website Live
The ORA’s new website is now online! Enjoy an improved design and user experience. Members can renew their membership and register for events.
Forteo now covered by EAP to treat AVN of jaw and Bisphosphonate-related atypical femoral fractures
Forteo now covered by EAP to treat AVN of jaw and Bisphosphonate-related atypical femoral fractures. Criteria for this can be found here
Drug Shortage Update
As many of you may be aware (especially our pediatric colleagues), there has been a recent unavailability of Naprosyn in liquid Suspension form. This product has been 'owned' by Roche Canada, for the Canadian market, but its manufacture had been outsourced to another Canadian company, who informed Roche in the Spring of 2013 that they would not be renewing their manufacturing agreement. Thus, Roche was unable to provide product (and were mistaken in their original belief that there were alternative sources available). This matter was brought to the attention of the CRA by Rosie Scuccimarri at Montreal Children's Hospital, and members of the ORA have been involved extensively with a process to resolve this untenable situation.
The ORA is pleased to annouce that the issue of Naprosyn Suspension shortage has been resolved. We would like to acknowledge the hard work of a quickly assembled committee that included Drs. Thorne, Scuccimarri, Levy, Benseler and our executive director, Denis Morrice. We would like to recognize the cooperation of Roche Canada. Pediapharm (Montreal) is a company that provides products that are pediatric specific, and will assume the DIN and become responsible for the manufacure and distribution of Naprosyn Suspension. Until Canadian manufacture is secured, the product will be imported from Orion (a Finnish company) and will be available through the Health Canada Special Access Program (SAP) for the next 8 to 12 months. Roche will continue to support the supply of this product until local manufacture starts. There will be no cost to the patient for Naprosyn Suspension during the SAP period. This is country wide. A Canadian manufactured Naprosyn Suspension is expected to be available through Pediapharm by March 2015. Further details, forms and FAQ's can be found on the CRA website.
Please follow the link to view the press announcement: http://www.stockhouse.com/news/press-releases/2014/07/02/pediapharm-inc-acquires-naproxen-suspension-from-hoffmann-la-roche-limited
Models of Care - May 2014
The Models of Care committee has identified several key initiatives to help to support the Ontario Framework. Click here for the communication piece.
- View All News
Upcoming Events for 2014
Diamond: The Arthritis Society, Pfizer Canada Inc., Amgen Canada Inc., Janssen Inc., Celgene Inc., Bristol-Myers Squibb Canada, Roche Canada
Platinum: GlaxoSmithKline Inc., UCB Canada Inc., AstraZeneca Canada Inc., Abbvie., Takeda Canada Inc.